Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1529060 | 0.97 | CETP (0.77) | CETPKCNH2 | |
| SCHEMBL12434946 | 0.94 | CETP (0.82) | CETPKCNH2 | |
| SCHEMBL12434865 | 0.94 | CETP (0.75) | CETPKCNH2 | |
| SCHEMBL12513229 | 0.90 | CETP (0.88) | CETPKCNH2 | |
| SCHEMBL1529079 | 0.90 | CETP (0.88) | CETPKCNH2 | |
| SCHEMBL1529018 | 0.90 | CETP (0.77) | CETPKCNH2 | |
| SCHEMBL14874695 | 0.90 | CETP (0.77) | CETPKCNH2 | |
| SCHEMBL12434898 | 0.90 | CETP (0.64) | CETPKCNH2 | |
| SCHEMBL14878820 | 0.90 | CETP (0.64) | CETPKCNH2 | |
| SCHEMBL12434951 | 0.89 | CETP (0.83) | CETPKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440702-B2 | 1,3-oxazolidin -2-one derivatives useful as CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20110178059-A1 | 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178059-A1 | 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | CETP, MTTP, APOB | CETP 1/4885KCNH2 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.